References
- Ding, Y., Lin, H., and Hsu, J. (2016), “Subgroup Mixable Inference on Treatment Efficacy in Mixture Populations, With an Application to Time-to-Event Outcomes,” Statistics in Medicine, 35, 1580–1594.
- Genz, A., and Bretz, F. (1999), “Numerical Computation of Multivariate t-Probabilities With Application to Power Calculation of Multiple Contrasts,” Journal of Statistical Computation and Simulation, 63, 361–378.
- Hsu, J. C. (1992), “The Factor Analytic Approach to Simultaneous Inference in the General Linear Model,” Journal of Computational and Graphical Statistics, 1, 151–168.
- Jiang, W., Freidlin, B., and Simon, R. (2007), “Biomarker-Adaptive Threshold Design: A Procedure for Evaluating Treatment With Possible Biomarker-Defined Subset Effect,” Journal of the National Cancer Institute, 99, 1036–1043.
- Miller, R., and Siegmund, D. (1982), “Maximally Selected chi Square Statistics,” Biometrics, 38, 1011–1016.
- Neumann, P. J., Cohen, J. T., and Weinstein, M. C. (2012), “Updating Cost-Effectiveness—The Curious Resilience of the $50, 000-Per-Qaly Threshold,” New England Journal of Medicine, 371, 796–797.
- Paré, G., Mehta, S. R., Yusuf, S., Anand, S. S., Connolly, S. J., Hirsh, J., Simonsen, K., Bhatt, D. L., Fox, K. A., and Eikelboom, J. W. (2010), “Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment,” New England Journal of Medicine, 363, 1704–1714.
- Ruberg, S. J., and Shen, L. (2015), “Personalized Medicine: Four Perspectives for Clinical Drug Development,” Statistics in Biopharmaceutical Research, 7, 214–229.
- Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., Lee, J. S., Mellemgaard, A., Park, K., Patil, S., Rolski, J., Goksel, T., de Marinis, F., Simms, L., Sugarman, K. P., and Gandara, D. (2008), “Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Nonsmall-Cell Lung Cancer,” Journal Of Clinical Oncology, 26, 3543–3551.
- Schnipper, L. E., Davidson, N., Wollins, D., Tyne, C., Blayney, D., Blum, D., Dicker, A., Ganz, P., Hoverman, J., Langdon, R., Lyman, G., Meropol, N., Mulvey, T., Newcomer, L., Peppercorn, J., Polite, B., Raghavan, D., Rossi, G., Saltz, L., Schrag, D., Smith, T. J., Yu, P. P., Hudis, C., and Schilsky, R. L. (2015), “American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options,” Journal of Clinical Oncology, 33, 2563–2577.
- Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., Ralph DAgostino, J., Ferdinand, K., Tay-lor, M., Adams, K., Sabolinski, M., Worcel, M., and Cohn, J. N. (2004), “Combination of Isosorbide Dinitrate and Hydralazine in Blacks With Heart Failure,” New England Journal of Medicine, 351, 2049–2057.
- Xu, H., and Hsu, J. C. (2007), “Using the Partitioning Principle to Control the Generalized Family Error Rate,” Biometrical Journal, 49, 52–67.
- Zhao, Y., Rush, D. Z. A. J., and Kosorok, M. R. (2012), “Estimating Individualized Treatment Rules Using Outcome Weighted Learning,” Journal of the American Statistical Association, 107, 1106–1118.